Have your own idea? Try our Stock Screener
U.S. Biotech Industry Analysis
UpdatedMay 22, 2025
DataAggregated Company Financials
Companies566
- 7D5.1%
- 3M-11.2%
- 1Y-14.9%
- YTD-6.1%
The Biotech industry is up 5.0% in the last week, with Gilead Sciences up 9.5%. Meanwhile, Biohaven actually underperformed within the industry, shrinking 20% in the last week. However, the industry is down 12% over the past year. As for the next few years, earnings are expected to grow by 24% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Thu, 22 May 2025 | US$925.6b | US$155.9b | -US$24,390,830,184.39 | 16x | -37.9x | 5.9x |
| Sat, 19 Apr 2025 | US$756.8b | US$119.2b | -US$36,619,881,205.07 | 19.4x | -20.7x | 6.3x |
| Mon, 17 Mar 2025 | US$838.7b | US$118.4b | -US$37,606,321,265.93 | 18.5x | -22.3x | 7.1x |
| Wed, 12 Feb 2025 | US$829.4b | US$117.8b | -US$35,710,278,673.37 | 17.4x | -23.2x | 7x |
| Fri, 10 Jan 2025 | US$967.2b | US$149.4b | -US$26,290,778,107.32 | 17.2x | -36.8x | 6.5x |
| Sun, 08 Dec 2024 | US$1.0t | US$150.0b | -US$26,481,489,967.01 | 17.9x | -39.1x | 6.9x |
| Tue, 05 Nov 2024 | US$1.1t | US$147.7b | -US$30,707,093,621.03 | 16.6x | -34.7x | 7.2x |
| Thu, 03 Oct 2024 | US$899.5b | US$113.2b | -US$35,974,034,598.12 | 21.4x | -25x | 7.9x |
| Sat, 31 Aug 2024 | US$906.2b | US$113.1b | -US$35,712,101,098.38 | 24x | -25.4x | 8x |
| Mon, 29 Jul 2024 | US$1.2t | US$164.9b | -US$28,965,808,648.76 | 26.4x | -43x | 7.5x |
| Wed, 26 Jun 2024 | US$1.2t | US$164.4b | -US$27,944,334,256.96 | 27.7x | -41.8x | 7.1x |
| Fri, 24 May 2024 | US$1.1t | US$164.6b | -US$26,730,942,218.01 | 23.8x | -42.8x | 7x |
| Sun, 21 Apr 2024 | US$1.1t | US$164.2b | -US$23,334,003,533.71 | 20.4x | -45.9x | 6.5x |
| Tue, 19 Mar 2024 | US$1.2t | US$167.4b | -US$21,842,633,160.51 | 13.6x | -52.9x | 6.9x |
| Thu, 15 Feb 2024 | US$1.1t | US$169.0b | -US$20,830,501,541.08 | 18.2x | -54.5x | 6.7x |
| Sat, 13 Jan 2024 | US$1.4t | US$204.8b | -US$22,497,556,941.00 | 18.8x | -63.9x | 7x |
| Mon, 11 Dec 2023 | US$1.3t | US$204.6b | -US$22,091,414,218.00 | 18.7x | -58.3x | 6.3x |
| Wed, 08 Nov 2023 | US$1.2t | US$203.9b | -US$22,098,875,636.00 | 17.7x | -56.1x | 6.1x |
| Fri, 06 Oct 2023 | US$1.3t | US$207.4b | -US$13,070,685,311.00 | 17x | -95.7x | 6x |
| Sun, 03 Sep 2023 | US$1.3t | US$207.6b | -US$12,424,624,459.00 | 18.4x | -104.2x | 6.2x |
| Tue, 01 Aug 2023 | US$1.2t | US$186.1b | -US$14,987,339,751.00 | 14.8x | -76.8x | 6.2x |
| Thu, 29 Jun 2023 | US$1.1t | US$186.2b | -US$16,022,072,383.00 | 13.5x | -69.8x | 6x |
| Sat, 27 May 2023 | US$1.1t | US$185.9b | -US$16,043,116,316.00 | 11.2x | -70x | 6x |
| Mon, 24 Apr 2023 | US$1.2t | US$198.4b | -US$3,220,153,400.00 | 13.9x | -369.7x | 6x |
| Wed, 22 Mar 2023 | US$1.1t | US$199.3b | -US$3,596,312,205.00 | 12.6x | -314x | 5.7x |
| Fri, 17 Feb 2023 | US$1.1t | US$202.6b | US$30.0m | 16.2x | 38090.5x | 5.6x |
| Sun, 15 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.5x | 670.9x | 5.8x |
| Tue, 13 Dec 2022 | US$1.2t | US$202.7b | US$1.4b | 14.7x | 821.2x | 5.7x |
| Thu, 10 Nov 2022 | US$1.1t | US$201.1b | US$920.9m | 12.9x | 1171.6x | 5.4x |
| Sat, 08 Oct 2022 | US$1.0t | US$206.1b | US$5.4b | 14.9x | 190.3x | 5x |
| Mon, 05 Sep 2022 | US$1.0t | US$206.4b | US$6.2b | 14.6x | 168.1x | 5x |
| Wed, 03 Aug 2022 | US$1.0t | US$211.8b | US$11.2b | 15.8x | 92.7x | 4.9x |
| Fri, 01 Jul 2022 | US$1.0t | US$212.2b | US$11.1b | 15.4x | 93.2x | 4.9x |
| Sun, 29 May 2022 | US$1.0t | US$212.7b | US$11.2b | 15.5x | 91.9x | 4.8x |
Price to Earnings Ratio
91.9x
Current Industry PE
- Investors are relatively neutral on the American Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.3x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 9.8% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | -1.15% | |
| Healthcare | 1.78% | |
| Biotech | 5.12% | |
| Biotech | 5.12% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| GILD Gilead Sciences | US$107.72 | 9.5% +US$11.6b | 58.9% | PE22.5x | |
| ABBV AbbVie | US$181.80 | 2.5% +US$7.7b | 13.9% | PE77.3x | |
| AMGN Amgen | US$271.34 | 3.5% +US$4.9b | -12.3% | PE24.6x | |
| VRTX Vertex Pharmaceuticals | US$435.32 | 3.4% +US$3.6b | -2.7% | PS10.1x | |
| REGN Regeneron Pharmaceuticals | US$604.62 | 5.8% +US$3.5b | -38.5% | PE14.2x |
